Unique ID issued by UMIN | UMIN000018627 |
---|---|
Receipt number | R000021555 |
Scientific Title | The efficacy and safety of live attenuated vaccine in patients treated with steroid and immunosuppresive drugs: A prospective study |
Date of disclosure of the study information | 2015/10/01 |
Last modified on | 2020/08/14 11:55:17 |
The efficacy and safety of live attenuated vaccine in patients treated with steroid and immunosuppresive drugs: A prospective study
The prospective study of live attenuated vaccine for patients treated with steroids and immunosuppresive drugs
The efficacy and safety of live attenuated vaccine in patients treated with steroid and immunosuppresive drugs: A prospective study
The prospective study of live attenuated vaccine for patients treated with steroids and immunosuppresive drugs
Japan |
collagen diseases, kidney diseases, digestive diaseases, liver diaseases, neurological diseases, kidney transplant patients
Pediatrics |
Others
NO
To evaluate the efficacy and safety of live attenuated vaccine in patients treated with steroid and immunosuppresive drugs
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
1) Assessment of antibody acquisition after vaccination classified by each virus.
2) Analysis of long maintenance of acquired immunity.
3) Analysis of incididence of adverse events.
1) Analysis of causes of vaccine failure.
2) Analysis of causes of adverse events.
3) Analysis of effect for prevention of virus infection.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Vaccine |
Live attenuated vaccine
1 | years-old | <= |
Not applicable |
Male and Female
1.Equal or more than one years old.
2. Patients under treatment with immunosuppressants(tacrolimus, cyclosporine, mizoribine, azathioprine, methotrexate mycophenolate mofetil)
3. Normal cellular immunity (CD4 counts>500/mm3, PHA lymphocyte stimulatory test-stimulation index>101.6).
4. Serum IgG level>300mg/dl
5. Negative or borderline antibody titer of one or more of the following viruses: measles, rubella, varicella, or mumps.
6. Patients under treatment with prednisolone <1mg/kg/day or <2mg/kg every alternate day.
7. tacrolimus trough level<10ng/ml or cyclosporine trough level<100ng/ml.
8. Patients with low activity of underlying disease.
9. Patients who cannot discontinue immunosuppressants because of primary disease.
1. Steroid use of more than 1mg/kg/d.
2. For renal transplant recipients, <1 year since transplantation or acute rejection within the previous 6 months.
80
1st name | Kenichi |
Middle name | |
Last name | Nishimura |
Yokohama City University
Department of Pediatrics
2360004
3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004 Japan
+81-45-787-2800
k_nsm@yokohama-cu.ac.jp
1st name | Kenichi |
Middle name | |
Last name | Nishimura |
Yokohama City University
Department of Pediatrics
2360004
3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004 Japan
+81-45-787-2671
k_nsm@yokohama-cu.ac.jp
Department of Pediatrics, Yokohama City University
Department of Pediatrics, Yokohama City University
Self funding
Yokohama City University
3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004 Japan
+81-45-787-2800
k_nsm@yokohama-cu.ac.jp
NO
横浜市立大学附属病院
2015 | Year | 10 | Month | 01 | Day |
Unpublished
Terminated
2015 | Year | 07 | Month | 09 | Day |
2015 | Year | 10 | Month | 01 | Day |
2015 | Year | 10 | Month | 01 | Day |
2021 | Year | 06 | Month | 30 | Day |
2021 | Year | 07 | Month | 31 | Day |
2021 | Year | 08 | Month | 31 | Day |
2021 | Year | 09 | Month | 30 | Day |
2015 | Year | 08 | Month | 10 | Day |
2020 | Year | 08 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021555